BioSpace News Archive

VoxNeuro Inc. (“VoxNeuro” or the “Company”), a commercial stage Software-as-a-Medical-Device (SaMD) brain health company that analyzes brain biomarkers to assess cognitive function, announced a new partnership with Boston University (“BU”), a world-class institution and private research university at the forefront of neuroscience and neurotechnology.

Arpeggio Biosciences, a preclinical therapeutics company whose technology targets transcriptional dysregulation in disease, and Builders VC, announced a $17 million dollar Series A funding round, following a $3.2 million dollar seed round completed in 2020.

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

RenovoRx, Inc. announced management’s participation in the upcoming H.C. Wainwright 24th Annual Global Investment Conference.

Edesa Biotech, Inc. announced that patient recruitment has been completed for a Phase 2b clinical study evaluating the company’s drug candidate, designated EB01, as a monotherapy for moderate-to-severe chronic Allergic Contact Dermatitis.

Xenetic Biosciences, Inc. announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Biotricity Inc., a medical diagnostic and consumer healthcare technology company, announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity’s innovative artificial intelligence-driven system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease.

Modular Medical Inc. announced that Jeb Besser, the Company’s Chief Executive Officer, will be participating in the following investor conferences:

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of the management team will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference.

Baxter International Inc., a global medtech leader, reinforced its commitment to expand the pipeline of Black healthcare professionals through several programs that support Black students pursuing health and science degrees at Historically Black Colleges and Universities.